Kalaris Therapeutics, Inc. (KLRS)
Nasdaq: KLRS · Biological Products, (No Diagnostic Substances) · Berkeley Heights, NJ · filing with the SEC since 2018
Who owns Kalaris Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
Srinivas Akkaraju holds 54.2% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13D/A filed May 22, 2026 says.
Directors and officers
14
report now, of 38 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Srinivas Akkaraju
SCHEDULE 13D/A · filed May 22, 2026 · Common Stock, $0.0001 par value per share · 56.5% in Feb 17, 2026
RTW Investments, LP
SCHEDULE 13G · filed Feb 17, 2026 · Common Stock, $0.0001 par value
Coastlands Capital LP
SCHEDULE 13G · filed Oct 26, 2026 · Common Stock, par value $0.0001 per share
Gilead Sciences, Inc.
SCHEDULE 13G/A · filed Mar 20, 2025 · Common Stock, $0.0001 per value · reported falling below 5%
Invus Public Equities, L.P.
SCHEDULE 13G/A · filed Jul 29, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
EcoR1 Capital, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock · reported falling below 5%, from 8.1% in Feb 14, 2025
What KLRS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Allo Vir
A company bought · acquisition · owns, named in the 10-K filed Mar 17, 2026
Kalaris Therapeutics, Inc.
A company bought · acquisition · owns, named in the 10-K filed Mar 17, 2026
3 subsidiaries in 3 countries, from the list filed with the 10-K filed Mar 17, 2026.
Insider tradesForm 4
1sales
0purchases
0sales on a scheduled plan
1people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 45 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Samsara Biocapital, L.P. | 10% owner | 0 | $0 | 0 | 1 | $1.2M |
| Samsara Opportunity Fund, L.P. | 10% owner | 0 | $0 | 0 | 1 | $5.0M |
| Hagen Brett R | Chief Accounting Officer | 1 | $0 | 0 | 0 | $0 |